当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > IL-21 is critical for GVHD in a mouse model.

IL-21 is critical for GVHD in a mouse model.

Abstract：

:Immunological effects of IL-21 on T, B and natural killer (NK) cells have been reported, but the role of IL-21 in GVHD remains obscure. Here, we demonstrate that morbidity and mortality of GVHD was significantly reduced after BMT with splenocytes from IL-21R(-/-) mice compared with those from wild type mice. To further confirm our observation, we generated a decoy receptor for IL-21. GVHD was again less severe in mice receiving BM cells transduced with the IL-21 decoy receptor than control mice These results suggest that IL-21 critically regulates GVHD, and that blockade of the IL-21 signal may represent a novel strategy for the prophylaxis for GVHD.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Meguro A,Ozaki K,Oh I,Hatanaka K,Matsu H,Tatara R,Sato K,Leonard WJ,Ozawa K

doi

10.1038/bmt.2009.223

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

723-9

issue

4

eissn

0268-3369

issn

1476-5365

pii

bmt2009223

journal_volume

45

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.

    abstract：:The aim of this study was to develop a comprehensive system for predicting non-relapse mortality after allogeneic hematopoietic cell transplantation (HCT) during first complete remission (CR) of acute myeloid leukemia (AML). After dividing 2344 eligible patients randomly into a training set and a validation set, we fi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01032-9

    authors： Yanada M,Konuma T,Mizuno S,Saburi M,Shinohara A,Tanaka M,Marumo A,Sawa M,Uchida N,Ozawa Y,Onizuka M,Yoshioka S,Nakamae H,Kondo T,Kimura T,Kanda J,Fukuda T,Atsuta Y,Nakasone H,Yano S

    更新日期：2020-08-14 00:00:00

  • Mismatched bone marrow transplantation for Omenn syndrome: a variant of severe combined immunodeficiency.

    abstract：:Omenn syndrome is a variant of SCID, inherited as an autosomal recessive disorder, and characterized by severe eczematoid dermatitis, eosinophilia, elevated serum IgE and a distinctive histology in enlarged lymph nodes. The etiology of Omenn syndrome is unknown, however, unlike other forms of SCID; patients with Omenn...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Loechelt BJ,Shapiro RS,Jyonouchi H,Filipovich AH

    更新日期：1995-09-01 00:00:00

  • Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).

    abstract：:Mafosfamide (ASTA-Z) is a chemotherapeutic agent currently in use for in vitro purging of tumor-bearing human BM cells prior to autologous bone marrow transplantation (ABMT). We tested the efficacy of ASTA-Z against mouse plasmacytoma cells MOPC-315 (MOPC), a model of human multiple myeloma. BALB/c mice were injected ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Weiss L,Slavin G,Reich S,Sidi H,Slavin S

    更新日期：1994-01-01 00:00:00

  • Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study.

    abstract：:We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to d...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1703759

    authors： Pytlík R,Benes P,Patorková M,Chocenská E,Gregora E,Procházka B,Kozák T

    更新日期：2002-12-01 00:00:00

  • Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - are there new strategies?

    abstract：:Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy. Oral complications may lead to dose reduction or delay in further cancer treatment. Mucositis can be caused directly by cytotoxic effects and indirectly by sustained neutropenia after cytostatic therapy. An impaired mucosal barrier ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1702024

    authors： Karthaus M,Rosenthal C,Ganser A

    更新日期：1999-11-01 00:00:00

  • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.

    abstract：:Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1700628

    authors： Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

    更新日期：1997-02-01 00:00:00

  • Successful allogeneic bone marrow transplant for chronic myeloid leukaemia despite previous interferon-induced cardiomyopathy.

    abstract：:We report a patient with CML who developed a reversible dilated cardiomyopathy with cardiac failure following 10 months of IFN therapy. Despite the previous cardiomyopathy, he tolerated subsequent allogeneic BMT without any adverse cardiac events. Reversible IFN-induced cardiomyopathy should not be considered a contra...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701188

    authors： Broady R,Hawkins T,Browett P,Palmer S

    更新日期：1998-04-01 00:00:00

  • The role of high-dose chemotherapy with autologous bone marrow transplantation in the treatment of breast cancer.

    abstract：:Autologous bone marrow reinfusion rapidly repopulates severely damaged bone marrow thus shortening the period of myelosuppression following high-dose chemotherapy programs. This strategy has been successfully employed in several hematologic malignancies such as acute leukemia, Hodgkin's disease, non-Hodgkin's lymphoma...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Hortobagyi GN

    更新日期：1988-11-01 00:00:00

  • Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies.

    abstract：:Patients receiving intensive cytotoxic therapy are traditionally supported with parenteral nutrition (PN), although it is unclear whether all patients benefit from PN. This study aimed to identify regimen-associated differences in PN requirements, to reveal discrepancies between the number of PN indications and the fr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701747

    authors： Iestra JA,Fibbe WE,Zwinderman AH,Romijn JA,Kromhout D

    更新日期：1999-05-01 00:00:00

  • (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

    abstract：:Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2010.339

    authors： Abou-Nassar KE,Stevenson KE,Antin JH,McDermott K,Ho VT,Cutler CS,LaCasce AS,Jacobsen ED,Fisher DC,Soiffer RJ,Alyea EP,Koreth J,Freedman AS

    更新日期：2011-12-01 00:00:00

  • Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers.

    abstract：:Hematopoietic progenitor cell levels were monitored in the peripheral blood of ten healthy adults receiving a single dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The objective was to determine the time and number of progenitor cells released into the peripheral blood, induced by a single ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Schwinger W,Mache C,Urban C,Beaufort F,Töglhofer W

    更新日期：1993-06-01 00:00:00

  • Gut protection by palifermin during autologous haematopoietic SCT.

    abstract：:Conditioning therapy in connection with haematopoietic SCT (HSCT) induces a disruption of the intestinal barrier function facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent increased risk of septicaemia and a worsening of GVHD in the allogeneic setting. Palifermin (recombinant...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.388

    authors： Johansson JE,Hasséus B,Johansson P,Eklöf C,Ohman D,Stockelberg D

    更新日期：2009-05-01 00:00:00

  • Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.

    abstract：:A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m(2) and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo-SCT was 326 (47-2189) days and median follow-up was 6.7 years. GVHD ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.267

    authors： Christopoulos P,Schmoor C,Waterhouse M,Marks R,Wäsch R,Bertz H,Finke J

    更新日期：2013-07-01 00:00:00

  • Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission.

    abstract：:Sixty-nine adolescents and adults 15-51 years of age with untreated acute lymphoblastic leukaemia (ALL, 54 patients) or lymphoblastic lymphoma (LL, 15 patients) were referred for intensive antileukaemic therapy. Patients were treated according to one of two protocols. Both included induction and consolidation with vin...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： De Witte T,Awwad B,Boezeman J,Schattenberg A,Muus P,Raemaekers J,Preijers F,Strijckmans P,Haanen C

    更新日期：1994-11-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract：:Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0536-y

    authors： Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期：2019-11-01 00:00:00

  • Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.

    abstract：:HSV can cause oral lesions that exacerbate chemotherapy-related mucositis. Intravenous acyclovir is effective in preventing HSV reactivations, but expensive. Valacyclovir has good bioavailability and has not been studied for prophylaxis of HSV among PCT patients. We compared the efficacy and costs of valacyclovir in p...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1703354

    authors： Dignani MC,Mykietiuk A,Michelet M,Intile D,Mammana L,Desmery P,Milone G,Pavlovsky S

    更新日期：2002-02-01 00:00:00

  • Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.

    abstract：:We retrospectively reviewed the pulmonary toxicity of six high dose chemotherapy protocols using four chemotherapy regimens in the treatment of solid tumors. All protocols used either high dose cyclophosphamide or ifosfamide in combination with one to three additional chemotherapeutic agents. In each protocol autologo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Seiden MV,Elias A,Ayash L,Hunt M,Eder JP,Schnipper LE,Frei E 3rd,Antman KH

    更新日期：1992-07-01 00:00:00

  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.

    abstract：:We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or malignant melanoma. Sixteen patients received IL-1 beta, 4 to 32 ng/kg/day administered subcutaneously for 7 days beginning 3 h after bone marrow infusion. Thr...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1700633

    authors： Elkordy M,Crump M,Vredenburgh JJ,Petros WP,Hussein A,Rubin P,Ross M,Gilbert C,Modlin C,Meisenberg B,Coniglio D,Rabinowitz J,Laughlin M,Kurtzberg J,Peters WP

    更新日期：1997-02-01 00:00:00

  • Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.

    abstract：:In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporate...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01165-x

    authors： Ahn JS,Kim T,Jung SH,Ahn SY,Jung SY,Song GY,Kim M,Yang DH,Lee JJ,Choi S,Lee JY,Park SK,Moon JH,Lee HY,Kim KH,Cai Y,Yi SY,Novitzky-Basso I,Zhang Z,Kim HJ,Kim DDH

    更新日期：2020-12-05 00:00:00

  • Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

    abstract：:Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticoster...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704829

    authors： Mayer J,Krejcí M,Doubek M,Pospísil Z,Brychtová Y,Tomíska M,Rácil Z

    更新日期：2005-04-01 00:00:00

  • ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature.

    abstract：:ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1704579

    authors： Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

    更新日期：2004-08-01 00:00:00

  • A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT.

    abstract：:Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was st...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/bmt.2009.337

    authors： Kanda Y,Yamashita T,Mori T,Ito T,Tajika K,Mori S,Sakura T,Hara M,Mitani K,Kurokawa M,Akashi K,Harada M

    更新日期：2010-08-01 00:00:00

  • Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.

    abstract：:Fifty patients with either lymphoid or selected solid tumor malignancies were apheresed an identical number of times for PBSC collection after being randomized to receive either G-CSF 10 microg/kg/day alone (arm I), or G-CSF at the same dose with GM-CSF 5 microg/kg/day (arm II). Growth factor(s) was/were given as the ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1700999

    authors： Spitzer G,Adkins D,Mathews M,Velasquez W,Bowers C,Dunphy F,Kronmueller N,Niemeyer R,McIntyre W,Petruska P

    更新日期：1997-12-01 00:00:00

  • Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

    abstract：:Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the ou...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2014.31

    authors： Cahu X,Chevallier P,Clavert A,Suarez F,Michallet M,Vincent L,Vigouroux S,Blaise D,Mariette C,Bilger K,Robin M,Yakoub-Agha I,Peffault de Latour R,Mohty M

    更新日期：2014-06-01 00:00:00

  • Diffuse alveolar hemorrhage following autologous bone marrow infusion.

    abstract：:Autologous BMT performed in a 57-year-old woman with relapsed large cell lymphoma was complicated by two consecutive episodes of diffuse alveolar hemorrhage (DAH). The second episode occurred immediately after infusion of autologous BM. DAH is an increasingly recognized complication of autologous BMT and carries a hig...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Corso S,Vukelja SJ,Wiener D,Baker WJ

    更新日期：1993-09-01 00:00:00

  • Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count.

    abstract：:IL-7 is produced by stromal cells and is the major lympho- and thymopoietic cytokine. IL-7 induces proliferation and differentiation of immature thymocytes, and protects thymocytes from apoptosis by induction of bcl-2 expression. The regulation of IL-7 production is poorly characterized, although down-regulation by tr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701655

    authors： Bolotin E,Annett G,Parkman R,Weinberg K

    更新日期：1999-04-01 00:00:00

  • Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation.

    abstract：:This study evaluated whether cytokine-induced blood stem cell mobilization also mobilized lymphoma cells and whether lymphoma cell mobilization affected outcome post autologous blood stem cell transplant. Blood stem cell collections from 26 non-Hodgkin's lymphoma (NHL) patients harvested during steady-state (non-mobil...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703124

    authors： Demirkazik A,Kessinger A,Armitage JO,Bierman PJ,Lynch J,Vose J,Chan W,Sharp JG

    更新日期：2001-07-01 00:00:00

  • Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?

    abstract：:Clostridium difficile is the most common cause of nosocomial diarrhea in the United States and Europe, and is a cause of significant morbidity and mortality among hospitalized patients. A newly identified epidemic strain has been associated with many hospital outbreaks of C. difficile-associated disease (CDAD), raisin...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2008.317

    authors： Bobak D,Arfons LM,Creger RJ,Lazarus HM

    更新日期：2008-12-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

    abstract：:The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.173

    authors： Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

    更新日期：2014-02-01 00:00:00

  • Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.

    abstract：:The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2013.53

    authors： Dispenzieri A,Seenithamby K,Lacy MQ,Kumar SK,Buadi FK,Hayman SR,Dingli D,Litzow MR,Gastineau DA,Inwards DJ,Micallef IN,Ansell SM,Johnston PB,Porrata LF,Patnaik MM,Hogan WJ,Gertz MA

    更新日期：2013-10-01 00:00:00